Amgen Inc. (NASDAQ:AMGN) Shares Sold by Roman Butler Fullerton & Co.

Roman Butler Fullerton & Co. decreased its position in Amgen Inc. (NASDAQ:AMGN) by 18.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,230 shares of the medical research company’s stock after selling 516 shares during the quarter. Roman Butler Fullerton & Co.’s holdings in Amgen were worth $717,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. Provence Wealth Management Group increased its stake in Amgen by 11.9% during the fourth quarter. Provence Wealth Management Group now owns 1,445 shares of the medical research company’s stock worth $416,000 after purchasing an additional 154 shares during the period. Kinsale Capital Group Inc. increased its stake in Amgen by 33.0% during the 4th quarter. Kinsale Capital Group Inc. now owns 11,348 shares of the medical research company’s stock worth $3,269,000 after buying an additional 2,814 shares during the period. Global Wealth Management Investment Advisory Inc. lifted its holdings in Amgen by 2.4% during the 4th quarter. Global Wealth Management Investment Advisory Inc. now owns 4,733 shares of the medical research company’s stock worth $1,363,000 after buying an additional 109 shares in the last quarter. Valley Brook Capital Group Inc. boosted its position in Amgen by 7.0% in the 4th quarter. Valley Brook Capital Group Inc. now owns 4,730 shares of the medical research company’s stock valued at $1,362,000 after buying an additional 310 shares during the period. Finally, Evergreen Wealth Management LLC boosted its position in Amgen by 1.7% in the 4th quarter. Evergreen Wealth Management LLC now owns 4,892 shares of the medical research company’s stock valued at $1,409,000 after buying an additional 84 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Argus increased their price objective on Amgen from $300.00 to $340.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. Mizuho increased their price target on Amgen from $223.00 to $235.00 and gave the company a “neutral” rating in a research report on Thursday, May 9th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $305.00 price objective (down from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. Bank of America upped their target price on shares of Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Finally, BMO Capital Markets lifted their price target on shares of Amgen from $336.00 to $355.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. Eleven investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $326.89.

Amgen Stock Performance

AMGN traded up $3.40 during trading on Tuesday, hitting $323.40. 1,624,886 shares of the stock were exchanged, compared to its average volume of 2,634,661. The company has a quick ratio of 0.98, a current ratio of 1.42 and a debt-to-equity ratio of 11.96. Amgen Inc. has a 1-year low of $248.38 and a 1-year high of $346.85. The stock has a fifty day moving average price of $318.64 and a two-hundred day moving average price of $298.86. The firm has a market capitalization of $173.48 billion, a P/E ratio of 45.71, a PEG ratio of 2.78 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). The business had revenue of $8.39 billion during the quarter, compared to analyst estimates of $8.35 billion. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The business’s revenue was up 20.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $5.00 earnings per share. As a group, sell-side analysts predict that Amgen Inc. will post 19.5 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Stockholders of record on Friday, August 16th were paid a dividend of $2.25 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 annualized dividend and a dividend yield of 2.78%. Amgen’s dividend payout ratio (DPR) is 128.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.